Militia Long/Short Equity ETF ORR
Set alert
38.49 USD -0.03 -0.08%
At close · Oct 30
38.49 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
38.41 Day range 38.87
31.51 52-week range 39.52
- YTD
- +12.68%
- 1 year
- +21.77%
- Open
- 38.87
- Prev close
- 38.52
- Mkt cap
- 37.50M
- Vol
- 94.44K
- Avg vol
- 52.98K
- EPS
- 2.99
- P/E
- 12.88
- Div yield
- 0.00%
More statistics
- Low
- 38.41
- High
- 38.87
6M chart
Signals (28)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 2026 | 3 days ago |
| MACD: Sell Signal | Oct 29, 2026 | 3 days ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 14, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 12, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 7, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 14, 2026 | 2 months ago |
| RSI: Overbought | Jul 30, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 27, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| SMA: Bearish | Jun 23, 2026 | 4 months ago |
| SMA: Bearish | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 27, 2026 | 5 months ago |
| SMA: Bearish | May 22, 2026 | 5 months ago |
| MACD: Sell Signal | May 22, 2026 | 5 months ago |
| SMA: Bearish | May 21, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 5 months ago |
| MACD: Buy Signal | May 6, 2026 | 5 months ago |
News
- Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
- Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
- New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026
- BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
- Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
- ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer
- /C O R R E C T I O N - AbbVie/
Your note
Sign in to keep a note on ORR — it syncs with the Stock Master app.